| [ Summary ] |
Research using genetically engineered mice which overexpress or lack specific cytokines has revealed an important role for proinflammatory cytokines such as IL-1, IL-6, TNF-alpha, and IFN-gamma or Th 1 cytokines including IL-2, IL-12, and IFN-gamma in the physiopathology of Crohn's disease. Knowledge obtained from these studies has moved from the laboratory into the clinic. Chimeric monoclonal antibodies for TNF-alpha, infliximab, are now on the market, and have been a powerful tool not only for the induction of remission but also for the maintenance of remission of active Crohn's disease. Pilot clinical trials of human anti-IL-6 receptor monoclonal antibodies in active Crohn's disease were successful. The results of clinical trials and knowledge obtained from clinical experience will be fed back in to basic research, and are expected to produce future therapies for Crohn's disease. |